

GSK completes divestment of travel vaccines to Bavarian Nordic

02 January 2020 | News

The decision to divest these brands supports GSK's strategic intent to increase focus and reinvest in growth assets



GlaxoSmithKline has announced the completion of the divestment of travel vaccines Rabipur (tradenname Rabavert in the US) for the prevention of rabies, and Encepur for the prevention of tick-borne encephalitis, to Bavarian Nordic.

Consistent with the terms of the agreement first announced on October 21st 2019, GSK has received an upfront payment of EUR308 million (£263m), and in due course will receive further milestone payments for a total consideration of up to EUR955 million.

The decision to divest these brands supports GSK's strategic intent to increase focus and reinvest in growth assets, innovation and a simplified supply chain in its vaccines business.

Rabipur is a well-established life-saving vaccine (rabies virus causes acute invariable fatal disease) with 30 years of market experience supported by extensive clinical and safety evidence and WHO pre-qualification. It is indicated both in persons bitten by suspect animals (PEP) and non-immune subjects at risk of rabies (PrEP).

Encepur is indicated for active immunization of high-risk populations against tick-borne encephalitis (TBE). It has unique dosing flexibility supported by proven efficacy and long-term persistence data.